Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (6087)	4/22/2008 7:35:53 AM
From: kenhott	Respond to of 7143

<FDA Investigates The FDA conducted an investigation and reported last week that although there were "small differences" between the two formulations, "they are not outside the established boundaries for equivalence." The generic did reach its maximum blood concentration in two to three hours, compared to five to six hours for Wellbutrin, but the FDA said those differences "were not considered clinically significant."> What a turkey comment, in general. It ain't a big secret that generics are sometimes not as good as branded. The FDA position is.. deal with it. What, no congressional investigation? I wonder what kind of drug plan they are on?